Lucy Scientific Discovery Inc. (NASDAQ: LSDI), an innovator in psychotropic drug development, proudly announces the launch of “Twilight” – a blend of Amanita and Reishi mushrooms that include a variety of other nootropics promoting improved cognitive function and enhanced sleep quality. This release comes on the heels of the recent launch of “Mindful” by Lucy. Both of these products are now available for purchase on the company’s official online store, www.buytrippy.com, as well as through Hightimes.com and other channels.
Twilight by Lucy is a product designed to enhance and optimize consumer’s nightly sleep. The introduction of Twilight alongside Mindful underscores Lucy Scientific Discovery’s dedication to providing solutions in the psychotropic marketplace.
“We are incredibly excited to present Twilight to our customers, and offer them a nightly solution for improved sleep. Sleep disorders, a pervasive issue faced by a significant proportion of the population, can significantly affect one’s overall well-being. After the encouraging reception of Mindful by Lucy, we are confident that Twilight will follow its success and enhance the lives of our customers.”
Chanel Perez, Director of Marketing of Lucy Scientific Discovery Inc
According to the National Heart, Lung, and Blood Institute, it is estimated that around 50 to 70 million adults in the United States suffer from sleep disorders. This represents approximately 15-20% of the adult population in the country. Additionally, the global sleep aids market is projected to grow to $125.3 billion in 2027.
The current formulations are available in capsule form, but will be made available in other formats in the near future.
To learn more about Twilight by Lucy and unlock the transformative power of better sleep, visit the company’s official Direct to Consumer platform at www.buytrippy.com/twilight.
About Lucy Scientific Discovery Inc.
Lucy Scientific Discovery Inc. (NASDAQ: LSDI) is a Nasdaq-listed company and a licensed producer of compounds for medicinal products. Holding a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances, Lucy Scientific Discovery Inc. and its wholly-owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver, and manufacture pharmaceutical-grade active pharmaceutical ingredients (APIs) used in controlled substances and their raw material precursors. Lucy does not sell psilocybin products to the general public. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery Inc. is dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide.